Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Efavirenz on Dalpiciclib (SHR6390) Pharmacokinetics in Healthy Subjects
NCT04973020Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Hengrui. Primary endpoints: Time to Maximum Plasma Concentration, Maximum Plasma Concentration and 3 more. Started Sep 2021; status: completed.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04973020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973020.